Trial Profile
An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2014 New trial record